Literature DB >> 23873029

Functions of TAp63 and p53 in restraining the development of metastatic cancer.

E H Tan1, J P Morton1, P Timpson2, P Tucci3, G Melino4, E R Flores5, O J Sansom1, K H Vousden1, P A J Muller1.   

Abstract

Many tumours harbour mutations in the p53 tumour-suppressor gene that result in the expression of a mutant p53 protein. This mutant p53 protein has, in most cases, lost wild-type transcriptional activity and can also acquire novel functions in promoting invasion and metastasis. One of the mechanisms underlying these novel functions involves the ability of the mutant p53 to interfere with other transcription factors, including the p53 family protein TAp63. To investigate whether simultaneous depletion of both p53 and TAp63 can recapitulate the effect of mutant p53 expression in vivo, we used a mouse model of pancreatic cancer in which the expression of mutant p53 resulted in the rapid appearance of primary tumours and metastases. As shown previously, loss of one allele of wild-type (WT) p53 accelerated tumour development. A change of one WT p53 allele into mutant p53 did not further accelerate tumour development, but did promote the formation of metastasis. By contrast, loss of TAp63 did not significantly accelerate tumour development or metastasis. However, simultaneous depletion of p53 and TAp63 led to both rapid tumour development and metastatic potential, although the incidence of metastases remained lower than that seen in mutant p53-expressing tumours. TAp63/p53-null cells derived from these mice also showed an enhanced ability to scatter and invade in tissue culture as was observed in mutant p53 cells. These data suggest that depletion of TAp63 in a p53-null tumour can promote metastasis and recapitulate-to some extent-the consequences of mutant p53 expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873029      PMCID: PMC4181588          DOI: 10.1038/onc.2013.287

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  51 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

2.  A functional enhancer of keratin14 is a direct transcriptional target of deltaNp63.

Authors:  Rose-Anne Romano; Barbara Birkaya; Satrajit Sinha
Journal:  J Invest Dermatol       Date:  2006-12-07       Impact factor: 8.551

3.  Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion.

Authors:  M Edward; C Gillan; D Micha; R H Tammi
Journal:  Carcinogenesis       Date:  2005-03-03       Impact factor: 4.944

4.  Role of p63 in Development, Tumorigenesis and Cancer Progression.

Authors:  Johann Bergholz; Zhi-Xiong Xiao
Journal:  Cancer Microenviron       Date:  2012-07-31

5.  Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells.

Authors:  C Quintavalle; E Donnarumma; M Iaboni; G Roscigno; M Garofalo; G Romano; D Fiore; P De Marinis; C M Croce; G Condorelli
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

6.  miR-203 represses 'stemness' by repressing DeltaNp63.

Authors:  A M Lena; R Shalom-Feuerstein; P Rivetti di Val Cervo; D Aberdam; R A Knight; G Melino; E Candi
Journal:  Cell Death Differ       Date:  2008-05-16       Impact factor: 15.828

7.  p63 induces key target genes required for epidermal morphogenesis.

Authors:  Maranke I Koster; Daisy Dai; Barbara Marinari; Yuji Sano; Antonio Costanzo; Michael Karin; Dennis R Roop
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

8.  Mutant p53 drives invasion in breast tumors through up-regulation of miR-155.

Authors:  P M Neilsen; J E Noll; S Mattiske; C P Bracken; P A Gregory; R B Schulz; S P Lim; R Kumar; R J Suetani; G J Goodall; D F Callen
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

Review 9.  p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.

Authors:  G Melino
Journal:  Cell Death Differ       Date:  2011-07-15       Impact factor: 15.828

10.  Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis.

Authors:  P Dong; M Karaayvaz; N Jia; M Kaneuchi; J Hamada; H Watari; S Sudo; J Ju; N Sakuragi
Journal:  Oncogene       Date:  2012-07-30       Impact factor: 9.867

View more
  18 in total

1.  Genomic analyses identify molecular subtypes of pancreatic cancer.

Authors:  Peter Bailey; David K Chang; Katia Nones; Amber L Johns; Ann-Marie Patch; Marie-Claude Gingras; David K Miller; Angelika N Christ; Tim J C Bruxner; Michael C Quinn; Craig Nourse; L Charles Murtaugh; Ivon Harliwong; Senel Idrisoglu; Suzanne Manning; Ehsan Nourbakhsh; Shivangi Wani; Lynn Fink; Oliver Holmes; Venessa Chin; Matthew J Anderson; Stephen Kazakoff; Conrad Leonard; Felicity Newell; Nick Waddell; Scott Wood; Qinying Xu; Peter J Wilson; Nicole Cloonan; Karin S Kassahn; Darrin Taylor; Kelly Quek; Alan Robertson; Lorena Pantano; Laura Mincarelli; Luis N Sanchez; Lisa Evers; Jianmin Wu; Mark Pinese; Mark J Cowley; Marc D Jones; Emily K Colvin; Adnan M Nagrial; Emily S Humphrey; Lorraine A Chantrill; Amanda Mawson; Jeremy Humphris; Angela Chou; Marina Pajic; Christopher J Scarlett; Andreia V Pinho; Marc Giry-Laterriere; Ilse Rooman; Jaswinder S Samra; James G Kench; Jessica A Lovell; Neil D Merrett; Christopher W Toon; Krishna Epari; Nam Q Nguyen; Andrew Barbour; Nikolajs Zeps; Kim Moran-Jones; Nigel B Jamieson; Janet S Graham; Fraser Duthie; Karin Oien; Jane Hair; Robert Grützmann; Anirban Maitra; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Richard A Morgan; Rita T Lawlor; Vincenzo Corbo; Claudio Bassi; Borislav Rusev; Paola Capelli; Roberto Salvia; Giampaolo Tortora; Debabrata Mukhopadhyay; Gloria M Petersen; Donna M Munzy; William E Fisher; Saadia A Karim; James R Eshleman; Ralph H Hruban; Christian Pilarsky; Jennifer P Morton; Owen J Sansom; Aldo Scarpa; Elizabeth A Musgrove; Ulla-Maja Hagbo Bailey; Oliver Hofmann; Robert L Sutherland; David A Wheeler; Anthony J Gill; Richard A Gibbs; John V Pearson; Nicola Waddell; Andrew V Biankin; Sean M Grimmond
Journal:  Nature       Date:  2016-02-24       Impact factor: 49.962

2.  A dual-regulated oncolytic adenovirus carrying TAp63 gene exerts potent antitumor effect on colorectal cancer cells.

Authors:  Qifeng Luo; Heying Liu; Zhenyu Zhang; Shiva Basnet; Zhenling Dai; Shuping Li; Yuxiang Wang; Bin Xu; Haiyan Ge
Journal:  Am J Transl Res       Date:  2017-06-15       Impact factor: 4.060

Review 3.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

4.  Association of SIRT1 and tumor suppressor gene TAp63 expression in head and neck squamous cell carcinoma.

Authors:  Keiji Kikuchi; Akira Noguchi; Rika Kasajima; Yohei Miyagi; Daisuke Hoshino; Naohiko Koshikawa; Akira Kubota; Tomoyuki Yokose; Yasuo Takano
Journal:  Tumour Biol       Date:  2015-05-07

5.  Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation.

Authors:  Brateil Badal; Alexander Solovyov; Serena Di Cecilia; Joseph Minhow Chan; Li-Wei Chang; Ramiz Iqbal; Iraz T Aydin; Geena S Rajan; Chen Chen; Franco Abbate; Kshitij S Arora; Antoine Tanne; Stephen B Gruber; Timothy M Johnson; Douglas R Fullen; Leon Raskin; Robert Phelps; Nina Bhardwaj; Emily Bernstein; David T Ting; Georg Brunner; Eric E Schadt; Benjamin D Greenbaum; Julide Tok Celebi
Journal:  JCI Insight       Date:  2017-05-04

6.  Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.

Authors:  Sebastian Kehrloesser; Christian Osterburg; Marcel Tuppi; Birgit Schäfer; Karen Heather Vousden; Volker Dötsch
Journal:  Cell Death Differ       Date:  2016-07-22       Impact factor: 15.828

7.  Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63α Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity.

Authors:  Xin Li; Zhongxian Tian; Honglei Jin; Jiheng Xu; Xiaohui Hua; Huiying Yan; Huating Liufu; Jingjing Wang; Jingxia Li; Junlan Zhu; Haishan Huang; Chuanshu Huang
Journal:  Mol Cell Biol       Date:  2018-10-15       Impact factor: 4.272

8.  The downregulation of ΔNp63 in p53-deficient mouse epidermal tumors favors metastatic behavior.

Authors:  Olga Bornachea; Fernando F López-Calderón; Marta Dueñas; Carmen Segrelles; Corina Lorz; Cristian Suárez-Cabrera; María Marañón; Beatriz Paradela-Dobarro; Mirentxu Santos; Jesús M Paramio
Journal:  Oncotarget       Date:  2015-09-15

9.  ΔNp63α activates CD82 metastasis suppressor to inhibit cancer cell invasion.

Authors:  J Wu; S Liang; J Bergholz; H He; E M Walsh; Y Zhang; Z-X Xiao
Journal:  Cell Death Dis       Date:  2014-06-05       Impact factor: 8.469

Review 10.  Mutant p53 in cancer: new functions and therapeutic opportunities.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Cancer Cell       Date:  2014-03-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.